|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chemotherapy and molecular targeting therapy for recurrent cervical cancer显示文摘For patients with primary stage IVB, persistent, or recurrent cervical cancer, chemotherapy remains the standard treatment, although it is neither curative nor associated with long-term disease control. In this review, we summarized the history of treatment of recurrent cervical cancer, and the current recommendation for chemotherapy and molecular targeted therapy. Eligible articles were identified by a search of the MEDLINE bibliographical database for the period up to November 30, 2014. The search strategy included the following any or all of the keywords: 'uterine cervical cancer', 'chemotherapy', and 'targeted therapies'. Since cisplatin every 21 days was considered as the historical standard treatment for recurrent cervical cancer, subsequent trials have evaluated and demonstrated activity for other agents including paclitaxel, gemcitabine, topotecan and vinorelbine among others. Accordingly, promising agents were incorporated into phase III trials. To examine the best agent to combine with cisplatin, several landmark phase III clinical trials were conducted by Gynecologic Oncology Group(GOG) and Japan Clinical Oncology Group(JCOG). Through, GOG204 and JCOG0505, paclitaxel/cisplatin(TP) and paclitaxel/carboplatin(TC) are now considered to be the recommended therapies for recurrent cervical cancer patients. However, the prognosis of patients who are already resistant to chemotherapy, are very poor. Therefore new therapeutic strategies are urgently required. Molecular targeted therapy will be the most hopeful candidate of these strategies. From the results of GOG240, bevacizumab combined with TP reached its primary endpoint of improving overall survival(OS). Although, the prognosis for recurrent cervical cancer patients is still poor, the results of GOG240 shed light on the usefulness of molecular target agents to chemotherapy in cancer patients. Recurrent cervical cancer is generally considered incurable and current chemotherapy regiments offer only modest gains in OS, particularly for patients with multiple poor prognostic factors. Therefore, it is crucial to consider not only the survival benefit, but also the minimization of treatment toxicity, and maximization of quality of life(QOL). | Naotake Tsuda Hidemichi Watari Kimio Ushijima | 2016 | Chinese Journal of Cancer Research2016，28，2： | 24 |
| 2 | Neoadjuvant chemotherapy for locally advanced cervical cancer显示文摘Neoadjuvant chemotherapy followed by surgery(NCS) has not been fully evaluated clinically. Currently, the main regimen of neoadjuvant chemotherapy(NAC) used in NCS includes cisplatin. The antitumor effects of NAC reduce lymph node metastasis and the tumor diameter in patients prior to surgery, and this can reduce the number of high risk patients who require postoperative radiation therapy. Many randomized controlled trials(RCTs) have examined the long-term prognosis of NCS compared to primary surgery, but the utility of NCS remains uncertain. The advent of concurrent chemoradiotherapy(CCRT) has markedly improved the outcome of radiotherapy(RT), and CCRT is now used as a standard method in many cases of advanced bulky cervical cancer. NCS gives a better treatment outcome than radiation therapy alone, but it is important to verify that NCS gives a similar or better outcome compared to CCRT. | Takashi Iwata Azumi Miyauchi Yukako Suga Hiroshi Nishio Masaru Nakamura Akiko Ohno Nobumaru Hirao Tohru Morisada Kyoko Tanaka Hiroki Ueyama Hidemichi Watari Daisuke Aoki | 2016 | Chinese Journal of Cancer Research2016，28，2： | 20 |
| 3 | Adjuvant chemotherapy for early-stage cervical cancer显示文摘The aim of this review is to address the current status of adjuvant chemotherapy alone in early-stage cervical cancer treatments in the literature. At present, the therapeutic effect of adjuvant chemotherapy alone after radical surgery(RS) has not yet been established, and radiation therapy(RT) or concurrent chemoradiotherapy(CCRT) is recommended as the standard adjuvant therapy after RS for early-stage cervical cancer in various guidelines. The main purpose of adjuvant therapy after RS, however, should be to reduce extrapelvic recurrence rather than local recurrence, although adjuvant RT or CCRT has survival benefits for patients with intermediate- or high-risk factors for recurrence. Moreover, several studies reported that adjuvant therapies including RT were associated with a higher incidence of complications, such as lymphedema, bowel obstruction and urinary disturbance, and a lower grade of long-term quality of life(QOL) or sexual functioning than adjuvant chemotherapy alone. The effect of adjuvant chemotherapy alone for early-stage cervical cancer with intermediate- or high-risk factors for recurrence were not fully investigated in prospective studies, but several retrospective studies suggest that the adjuvant effects of chemotherapy alone are at least similar to that of RT or CCRT in terms of recurrence rate, disease-free survival, or overall survival(OS) with lower incidence of complications. Whereas cisplatin based combination regimens were used in these studies, paclitaxel/cisplatin(TP) regimen, which is currently recognized as a standard chemotherapy regimen for patients with metastatic, recurrent or persistent cervical cancer by Gynecologic Oncology Group(GOG), had also survival benefit as an adjuvant therapy. Therefore, it may be worth considering a prospective randomized controlled trial(RCT) of adjuvant chemotherapy alone using TP regimen versus adjuvant RT as an alternative adjuvant therapy. Because early-stage cervical cancer is a curable condition, it is necessary that the therapeutic strategies should be improved with considering adverse events and QOL for long-term survivors. | Hiroshi Asano Yukiharu Todo Hidemichi Watari | 2016 | Chinese Journal of Cancer Research2016，28，2： | 10 |
| 4 | Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups显示文摘Concurrent chemoradiotherapy(CCRT) is regarded as the standard treatment for locally advanced uterine cervical cancer(LACC), including stage Ib2-IVa disease [International Federation of Gynecology and Obstetrics(FIGO) staging]. However, approximately a third of eligible patients in previous studies died of LACC despite receiving CCRT. The therapeutic significance of CCRT alone in stage III-IVa disease has not yet been confirmed. Effective treatment of some LACC is beyond the scope of CCRT. The objective of the present review is to highlight some challenging work aimed at overcoming this seemingly intractable disease. CCRT with increased peak concentrations of cisplatin(CDDP), surgery following CCRT, adjuvant chemotherapy(CT) following CCRT, and neoadjuvant CT followed by CCRT are strategies expected to enhance the therapeutic efficacy of CCRT. If patients with LACC were divided into those with low-risk or high-risk systemic disease or prognoses, novel strategies should be assessed in the group with high-risk disease. | Yukiharu Todo Hidemichi Watari | 2016 | Chinese Journal of Cancer Research2016，28，2： | 7 |
| 5 | Apoptosis and Molecular Targeting Therapy in Cancer显示文摘 | Mohamed Hassan Hidemichi Watari Ali AbuAlmaaty Yusuke Ohba Noriaki Sakuragi Elena Orlova | 2014 | BioMed Research International2014，，： | 2 |
| 6 | Tumor volume successively reflects the state of disease progression in endometrial cancer显示文摘 | Yukiharu Todo Hidemichi Watari Kazuhira Okamoto Hitoshi Hareyama Shinichiro Minobe Hidenori Kato Noriaki Sakuragi | 2013 | Gynecologic Oncology2013，，3： | 1 |
| 7 | Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis显示文摘 | Yukiharu Todo Hidenori Kato Masanori Kaneuchi Hidemichi Watari Mahito Takeda Noriaki Sakuragi | 2010 | The Lancet2010，，9721： | 1 |
| 8 | Treatment of cervical cancer with adjuvant chemotherapy versus adjuvant radiotherapy after radical hysterectomy and systematic lymphadenectomy显示文摘 | Hosaka Masayoshi Watari Hidemichi Takeda Mahito | 2008 | J Obstet Gynaecol Res2008，34，4： | 1 |
| 9 | High prevalence of multiple human papillomavirus infection in Japanese patients with invasive uterine cervical cancer显示文摘 | Watari Hidemichi Michimata | | 0，，04： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员